Personalised immunotherapy in active multiple sclerosis using injectable cladrib- ine: Follow-up of the BartsMS cohort

• DOI: 10.1136/jnnp-2022-abn.6
• Publication Date: 2022-05-27T11:35:45Z
• Authors: Kimberley Allen-P...; Stefania De Trane; Ozlem Yildiz; Ashok Adams; Ben Turner; Monica Marta; Joela Mathews; Dan Altmann; Gavin Giovannoni; Klaus Schmierer
• Keywords: Cladribine; Tolerability

Introduction Cladribine tablets (Mavenclad®) are licensed for treating people with relapsing multiple sclerosis (pwRMS). We treated (pwRMS) and progressive MS (pwPMS) using sub- cutaneously administered cladribine (SCAC) since 2014. Here, we present up to five year follow-up on safety efficacy. Methods SCAC 10mg was given 3–4 days during week 1. 0–3 doses were at 5, according 4 lymphocyte count. A second cycle of 11 months later. Follow-up included clinical outcome evaluation pharmacovigilance. The proportion pwMS no evidence (i) disease activity (NEDA) (ii) progression or active (NEPAD) calculated. Results 211 received SCAC. 154/211 completed two treatment cycles. At baseline age 44 (17–72) years, EDSS 1–8.5. Tolerability good. One myocardial infarction one breast cancer occurred. Two severely disabled died (one influenza, encephalitis). Lymphopenia grade 3 detected in <3%. 2 71% (CI 54%, 85%) pwRMS had NEDA; 38% 23%, 54%) pwPMS NEPAD. Conclusions well tolerated. Frequency significant lymphopenia low. Efficacy corresponds trial data. NEPAD rates similar DMT. [e-mail]